EIC Summit 25 Networking Platform

2 – 3 Apr 2025 | Brussels, Belgium

InvestmentUpdated on 24 March 2025

Serie A

Nathalie Donne

CEO at ErVimmune

Lyon, France

About

Our current Series A target is €10M. To date, €8.5M are already secured from the European Investment Bank (€5M), Seventure (€2.5M), and SPRIM (€0.75M to €1M).

The proceeds from this Series A round will fund our pharmaceutical development in collaboration with our CDMO partner, and enable our First-in-Human trial. This study aims to evaluate the safety and efficacy of our durg candidate in combination with an immune checkpoint inhibitor, such as pembrolizumab, in patients with relapsed/refractory advanced or metastatic TNBC.

We are eager to finalize this Series A and move forward to the clinic as soon as possible!

Organisation

ErVimmune

Start-ups and SMEs

Lyon, France

Similar opportunities